|
Article Cited by others ORIGINAL ARTICLE
A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer
Vijjan Vivek, Mandhani Anil, Kapoor Rakesh, Dubey Deepak, Srivastava Aneesh, Ansari M S, Singh Pratipal, Kumar Anant
Year : 2006| Volume: 22| Issue : 4 | Page no: 317-321 | This article has been cited by | | 1 |
XRCC1 codon 399 mutant allele: A risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy |
|
| | Mittal, R.D., Singh, R., Manchanda, P.K., Ahirwar, D., Gangwar, R., Kesarwani, P., Mandhani, A. | | | Cancer Biology and Therapy. 2008; 7(5): 647-652 | | | [Pubmed] [Google Scholar] | | | 2 |
Bacillus Calmette-Guerin in the management of superficial bladder cancer |
|
| | Kapoor, R., Vijjan, V., Singh, P. | | | Indian Journal of Urology. 2008; 24(1): 72-76 | | | [Pubmed] [Google Scholar] | | | 3 |
The Safety and Efficacy of Different Doses of Bacillus Calmette Guérin in Superficial Bladder Transitional Cell Carcinoma |
|
| | Agrawal, M.S. and Agrawal, M. and Bansal, S. and Agarwal, M. and Lavania, P. and Goyal, J. | | | Urology. 2007; 70(6): 1075-1078 | | | [Pubmed] [Google Scholar] | | | 4 |
The Safety and Efficacy of Different Doses of Bacillus Calmette Guérin in Superficial Bladder Transitional Cell Carcinoma |
|
| | Madhu S. Agrawal,Moneet Agrawal,Sumit Bansal,Mayank Agarwal,Prashant Lavania,Jitendra Goyal | | | Urology. 2007; 70(6): 1075 | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
|
|
